Rapid glycemic regulation in poorly controlled patients living with diabetes, a new associated factor in the pathophysiology of Charcot's acute neuroarthropathy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 32437409.
- Also identified by DOI 10.1371/journal.pone.0233168 and PMC identifier 7241699.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aggressive antidiabetic therapy and rapid glycemic control are associated with diabetic neuropathy. Here we investigated if this is also the case for Charcot neuroarthropathy. HbA1c levels and other relevant data were extracted from medical databases of 44 cases of acute Charcot neuroarthropathy. HbA1c levels significantly declined from 8.25% (67mmol/mol) [7.1%-9.4%](54-79mmol/mol), at -6 months (M-6), to 7.40%(54mmol/mol) [6.70%-8.03%] (50-64 mmol/mol) during the six months preceding the diagnosis of Charcot neuroarthropathy (P <0.001). HbA1c levels significantly declined during the six months preceding the onset of Charcot neuroarthropathy. This decline seems to be a associated factor with the appearance of an active phase of Charcot neuroarthropathy in poorly controlled patients with diabetic sensitive neuropathy.
Medical subject headings
- Amyotrophic Lateral Sclerosis
- Diabetic Nephropathies
- Glycated Hemoglobin
- Hypoglycemic Agents